Menu
Share this

PPD Recognized for Excellence in Clinical Research in CRO Leadership Awards

Honored for expertise, capabilities, reliability, compatibility and quality

15 Mar. 2016

RSS

WILMINGTON, N.C., (March 15, 2016) – Pharmaceutical Product Development, LLC (PPD) today announced it has been recognized for excellence in clinical research by pharmaceutical and biotechnology executives surveyed for Life Science Leader magazine’s 2016 CRO Leadership Awards.

PPD earned honors in 11 distinct categories in clinical research, including expertise, capabilities, reliability, compatibility and quality. The honors are based on survey responses from more than 2,200 biopharmaceutical industry leaders responsible for making or influencing decisions to collaborate with contract research organizations (CROs) on clinical development programs.

PPD’s service offerings span the value chain of clinical research, with integrated Phase I-IV services and PPD® Laboratories, offering the most comprehensive lab services available in the industry.

“PPD’s purpose and mission are to improve health by helping our customers deliver life-changing therapies,” said David Simmons, chairman and CEO of PPD. “Being recognized for excellence by the industry leaders best positioned to judge our progress is gratifying.  The recognition reflects our dedication to the highest quality service delivery and our strategy of bending the cost and time curve of drug development, to get therapies to patients faster and to improve the productivity of our customers’ R&D investments. As our customers’ needs continue to evolve, we remain committed to continuous improvement and innovation to address the difficult challenges affecting the biopharmaceutical industry in our shared mission of delivering life-changing medicines to improve health.”

The Life Science Leader 2016 CRO Leadership Awards were based on surveys, encompassing 27 performance metrics, conducted by Industry Standard Research, a full-service pharmaceutical market research firm, to help the publication assess the performance of CROs.

About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug developmentlaboratory and lifecycle management services. Our clients and partners include pharmaceuticalbiotechnologymedical device, academic and government organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health.

Forward-Looking Statement

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s award-winning client services contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Contact Us

Upcoming Tradeshows and Speaker Events

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.